TG Therapeutics, Inc. splits its revenue into 2 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Product at $235.8 million, 98% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
800
|
240
|
205
|
193
|
162
|
141
|
121
|
108
|
84
|
| Product |
786
+74.9%
share 98.2%
|
236
+69.8%
share 98.1%
|
201
+68.2%
share 98.2%
|
189
+76.2%
share 98.2%
|
159
+91.3%
share 98.5%
|
139
share 98.4%
|
120
share 99.0%
|
107
share 99.2%
|
83
share 99.3%
|
| License |
14
+184.2%
share 1.8%
|
5
+97.0%
share 1.9%
|
4
+200.6%
share 1.8%
|
3
+313.0%
share 1.8%
|
2
+311.0%
share 1.5%
|
2
share 1.6%
|
1
share 1.0%
|
1
share 0.8%
|
1
share 0.7%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TGTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1001316
- Former names
- MANHATTAN PHARMACEUTICALS INC (until Apr 27, 2012); ATLANTIC TECHNOLOGY VENTURES INC (until Mar 10, 2003); ATLANTIC PHARMACEUTICALS INC (until Feb 4, 2000)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.